<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>International AIDS Society</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Coinfections and diversity paint the many shades of HIV cure</title>
      <description>
        <![CDATA[We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses and bacteria, but also with mechanisms occurring within the body, such as microbiome metabolism, the effects of aging, or the development of diseases. At a preconference session at the 13th IAS Conference on HIV Science (IAS 2025), scientists explained the interactions of different microorganisms with HIV.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722379</guid>
      <pubDate>Tue, 22 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722379-coinfections-and-diversity-paint-the-many-shades-of-hiv-cure</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/AdobeStock_411836983.webp?t=1745260197" type="image/jpeg" medium="image" fileSize="427124">
        <media:title type="plain">HIV virus cells</media:title>
      </media:content>
    </item>
    <item>
      <title>IAS 2025: Cheat, parasitize, break the virus – fresh ideas fuel HIV research</title>
      <description>
        <![CDATA[There is still no effective vaccine or cure for HIV. Scientists are considering options ranging from longer-term antiretroviral therapy (ART) that space out injections by several years to long-lasting pre-exposure prophylaxis (PrEP) that acts as a vaccine while immunization is achieved. What else can be done?]]>
      </description>
      <guid>http://www.bioworld.com/articles/722401</guid>
      <pubDate>Mon, 21 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722401-ias-2025-cheat-parasitize-break-the-virus-fresh-ideas-fuel-hiv-research</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-HIV-1-virus-particles.webp?t=1719502120" type="image/jpeg" medium="image" fileSize="549861">
        <media:title type="plain">Transmission electron micrograph of HIV-1 virus particles </media:title>
        <media:description type="plain">Transmission electron micrograph of HIV-1 virus particles (red/yellow) budding and replicating from a segment of a chronically infected H9 cell (blue/teal). Credit: NIAID, NIH</media:description>
      </media:content>
    </item>
    <item>
      <title>IAS 2025: Cheat, parasitize, break the virus – fresh ideas fuel HIV research</title>
      <description>
        <![CDATA[There is still no effective vaccine or cure for HIV. Scientists are considering options ranging from longer-term antiretroviral therapy (ART) that space out injections by several years to long-lasting pre-exposure prophylaxis (PrEP) that acts as a vaccine while immunization is achieved. What else can be done? The “Innovations in HIV virology: Translating discoveries into novel therapies” symposium in basic science at the 13th IAS Conference on HIV Science (IAS 2025), which took place from July 13 to 17, 2025, in Kigali, Rwanda, showcased some of the new ideas that the scientific community are developing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722313</guid>
      <pubDate>Fri, 18 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722313-ias-2025-cheat-parasitize-break-the-virus-fresh-ideas-fuel-hiv-research</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-HIV-1-virus-particles.webp?t=1719502120" type="image/jpeg" medium="image" fileSize="549861">
        <media:title type="plain">Transmission electron micrograph of HIV-1 virus particles </media:title>
        <media:description type="plain">Transmission electron micrograph of HIV-1 virus particles (red/yellow) budding and replicating from a segment of a chronically infected H9 cell (blue/teal). Credit: NIAID, NIH</media:description>
      </media:content>
    </item>
    <item>
      <title>IAS 2025: All eyes still on the HIV reservoir</title>
      <description>
        <![CDATA[While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent state within cellular reservoirs that scientists do not know how to eliminate. “Transcription is a critical step in the viral life cycle. … But there are currently no drugs suppressing HIV transcription, and that may be one of the reasons why current antiretroviral therapy is not curative,” Melanie Ott told the audience at the 13th IAS Conference on HIV Science this week in Kigali, Rwanda.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722226</guid>
      <pubDate>Wed, 16 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722226-ias-2025-all-eyes-still-on-the-hiv-reservoir</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NHI-NIAID-HIV-1-virus-particles-pink.webp?t=1752677386" type="image/jpeg" medium="image" fileSize="1133167">
        <media:title type="plain">Transmission electron micrograph of HIV-1 virus particles</media:title>
        <media:description type="plain">HIV-1 virus particles. Credit: NIAID, CC BY 2.0</media:description>
      </media:content>
    </item>
    <item>
      <title>Working backward from the goal is promising HIV vaccine strategy</title>
      <description>
        <![CDATA[The 2024 meeting of the International AIDS Society (IAS) is wrapping up as the 2024 Olympic Games are about to begin. That timing was probably what prompted the use of multiple sports analogies at Thursday’s plenary session on HIV prevention strategies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711077</guid>
      <pubDate>Tue, 30 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711077-working-backward-from-the-goal-is-promising-hiv-vaccine-strategy</link>
    </item>
    <item>
      <title>Working backward from the goal is promising HIV vaccine strategy</title>
      <description>
        <![CDATA[Last week, the 2024 meeting of the International AIDS Society (IAS) was wrapping up as the 2024 Olympic Games were about to begin. That timing was probably what prompted the use of multiple sports analogies at Thursday’s plenary session on HIV prevention strategies. Given the decades-long attempts at developing an HIV vaccine, Peter Piot, past IAS president and director emeritus and professor at the London School of Hygiene and Tropical Medicine, said in his introduction: “This is clearly a marathon. But marathons also finish.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/711047</guid>
      <pubDate>Mon, 29 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711047-working-backward-from-the-goal-is-promising-hiv-vaccine-strategy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Vaccine-development.webp?t=1722265123" type="image/jpeg" medium="image" fileSize="108559">
        <media:title type="plain">Syringe with illustration of molecules</media:title>
      </media:content>
    </item>
    <item>
      <title> Working backward from the goal is promising HIV vaccine strategy</title>
      <description>
        <![CDATA[The 2024 meeting of the International AIDS Society (IAS) is wrapping up as the 2024 Olympic Games are about to begin. That timing was probably what prompted the use of multiple sports analogies at Thursday’s plenary session on HIV prevention strategies. Given the decades-long attempts at developing an HIV vaccine, Peter Piot, past IAS president and director emeritus and professor at the London School of Hygiene and Tropical Medicine, said in his introduction: “This is clearly a marathon. But marathons also finish.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/711045</guid>
      <pubDate>Fri, 26 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711045-working-backward-from-the-goal-is-promising-hiv-vaccine-strategy</link>
    </item>
    <item>
      <title>Gilead’s GS-1720 permits once-weekly oral administration</title>
      <description>
        <![CDATA[Integrase strand transfer inhibitors (INSTI) under a once-daily oral schedule are the standard-of-care treatment for HIV. Longer-acting oral and injectable formulations to facilitate adherence to treatment regimens are needed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710831</guid>
      <pubDate>Thu, 25 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710831-gileads-gs-1720-permits-once-weekly-oral-administration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/HIV-drugs.webp?t=1624388970" type="image/png" medium="image" fileSize="390952">
        <media:title type="plain">HIV drugs</media:title>
      </media:content>
    </item>
    <item>
      <title>IAS 2024: Seventh HIV cure reported, but broad reach will take other approaches </title>
      <description>
        <![CDATA[The 2024 meeting of the International AIDS Society (IAS), which is being held in Munich this week, began with the announcement of another curative bone marrow transplant. The new case brings the total number of patients cured of HIV via a bone marrow transplant up to 7 since “Berlin patient” Timothy Ray Brown became the first such person in 2007.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710677</guid>
      <pubDate>Mon, 22 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710677-ias-2024-seventh-hiv-cure-reported-but-broad-reach-will-take-other-approaches</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/HIV-AIDS-viral-structure.webp?t=1707321297" type="image/jpeg" medium="image" fileSize="238698">
        <media:title type="plain">Cross section illustration of HIV virus parts</media:title>
      </media:content>
    </item>
    <item>
      <title>IAS 2023: Will long-acting treatments be the next game changer for people living with HIV? </title>
      <description>
        <![CDATA[For people living with HIV, the single greatest achievement to date has been the emergence of antiretroviral treatments (ART) that completely block the virus, resulting in reduced mortality and morbidity and improved quality of life. But taking one pill a day for life cannot be the end of this journey, speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/699789</guid>
      <pubDate>Tue, 08 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699789-ias-2023-will-long-acting-treatments-be-the-next-game-changer-for-people-living-with-hiv</link>
    </item>
    <item>
      <title>IAS 2023: Will long-acting treatments be the next game changer for people living with HIV? </title>
      <description>
        <![CDATA[For people living with HIV, the single greatest achievement to date has been the emergence of antiretroviral treatments (ART) that completely block the virus, resulting in reduced mortality and morbidity and improved quality of life. But taking one pill a day for life cannot be the end of this journey, speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia. Even with the success of ART, drug adherence remains a problem due to pill fatigue or depression and other mental health conditions, as well as drug-drug interactions, said Claudia Cortes, associate professor at the University of Chile in Santiago. New drugs that are longer lasting, more convenient, and affordable are desperately needed, she said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699624</guid>
      <pubDate>Wed, 02 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699624-ias-2023-will-long-acting-treatments-be-the-next-game-changer-for-people-living-with-hiv</link>
    </item>
    <item>
      <title>IAS 2023: Broadly neutralizing antibodies bring potential cure for HIV closer (part 2)</title>
      <description>
        <![CDATA[Broadly neutralizing antibodies (bNAbs) have the potential to prevent HIV, and more researchers are turning to bNAbs as an alternative to antiretroviral therapy (ART), speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia. However, for a cure, the viral reservoir that is formed in the early stages of HIV remains an obstacle, and recent studies suggest that controlling or eliminating the HIV reservoir with bNAbs might be possible.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699570</guid>
      <pubDate>Tue, 01 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699570-ias-2023-broadly-neutralizing-antibodies-bring-potential-cure-for-hiv-closer-part-2</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/HIV-infected-cell-Credit-NIAID.webp?t=1772724323" type="image/png" medium="image" fileSize="757353">
        <media:title type="plain">HIV-infected cell</media:title>
        <media:description type="plain">HIV-infected cell. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>IAS 2023: Broadly neutralizing antibodies bring potential cure for HIV closer (part 2)</title>
      <description>
        <![CDATA[Broadly neutralizing antibodies (bNAbs) have the potential to prevent HIV, and more researchers are turning to bNAbs as an alternative to antiretroviral therapy (ART), speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699251</guid>
      <pubDate>Fri, 28 Jul 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699251-ias-2023-broadly-neutralizing-antibodies-bring-potential-cure-for-hiv-closer-part-2</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/HIV-infected-cell-Credit-NIAID.webp?t=1772724323" type="image/png" medium="image" fileSize="757353">
        <media:title type="plain">HIV-infected cell</media:title>
        <media:description type="plain">HIV-infected cell. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>All together now: Cures and reservoirs at IAS 2021</title>
      <description>
        <![CDATA[The complete relegation of conferences to cyberspace that began with one HIV conference, CROI 2020, ended with another, the 2021 IAS meeting. Though the conference was still largely virtual, there was also an in-person component held in Berlin.]]>
      </description>
      <guid>http://www.bioworld.com/articles/509580</guid>
      <pubDate>Wed, 21 Jul 2021 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/509580-all-together-now-cures-and-reservoirs-at-ias-2021</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/HIV-infected-cell-Credit-NIAID.webp?t=1772724323" type="image/png" medium="image" fileSize="757353">
        <media:title type="plain">HIV-infected cell</media:title>
        <media:description type="plain">HIV-infected cell. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>AIDS2020: Virtual: Can state of the ART get to ‘see you next year’?</title>
      <description>
        <![CDATA[Forty years after HIV became a global pandemic, there are now more than 30 drugs approved to treat it. The National Institute of Allergy and Infectious Diseases’ director, Anthony Fauci, and clinical director, Clifford Lane, opined in the July 2, 2020, issue of <em>The New England Journal of Medicine</em> that “considering the spectacular scientific advances that have been made over nearly four decades, it is conceivable that with optimal implementation of available prevention strategies and treatments, the end of HIV/AIDS as a global pandemic will be attainable.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/436314</guid>
      <pubDate>Wed, 08 Jul 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436314-aids2020-virtual-can-state-of-the-art-get-to-see-you-next-year</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Jul-2020/Science-7-8-HIV-capsid.webp?t=1594237761" type="image/png" medium="image" fileSize="549934">
        <media:title type="plain">HIV encased in multiple structures including the capsid (blue)</media:title>
        <media:description type="plain">HIV is encased in multiple structures including the capsid,
shown in blue. Credit: Juan Perilla
</media:description>
      </media:content>
    </item>
    <item>
      <title>HCV’s success makes for HBV ‘feeding frenzy’</title>
      <description>
        <![CDATA[MEXICO CITY – A hepatitis B virus (HBV) cure was considered “a pipe dream for many years,” Anna Kramvis, of the University of Witwatersrand, told the audience at the 2019 HIV & HBV Cure Forum, co-organized by the International AIDS Society (IAS) Towards an HIV Cure initiative and the International Coalition to Eliminate Hepatitis B (ICE-HBV). Kramvis is also on the board of ICE-HBV]]>
      </description>
      <guid>http://www.bioworld.com/articles/398023</guid>
      <pubDate>Mon, 29 Jul 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/398023-hcvs-success-makes-for-hbv-feeding-frenzy</link>
    </item>
    <item>
      <title>Vaccine trials seek to maximize potential, manage expectations</title>
      <description>
        <![CDATA[MEXICO CITY – Ten years after the RV144 "Thai trial" was the first to show that an effective HIV vaccine was possible, three efficacy trials for HIV vaccines are once again underway.]]>
      </description>
      <guid>http://www.bioworld.com/articles/337951</guid>
      <pubDate>Wed, 24 Jul 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/337951-vaccine-trials-seek-to-maximize-potential-manage-expectations</link>
    </item>
    <item>
      <title>HBV cures discussed at HIV meeting</title>
      <description>
        <![CDATA[MEXICO CITY – The 2019 International AIDS Society (IAS) Conference on HIV Science kicked off over the weekend with the usual pre-conference workshops, including a workshop by the IAS Towards an HIV Cure initiative.]]>
      </description>
      <guid>http://www.bioworld.com/articles/330771</guid>
      <pubDate>Tue, 23 Jul 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/330771-hbv-cures-discussed-at-hiv-meeting</link>
    </item>
  </channel>
</rss>
